While alterations in the DDR pathway and KEAP1/NFE2L2 were not functionally validated, we did use OncoKB, an FDA-recognized tumor mutational database, to categorize alterations identified by tissue-based sequencing in this cohort.15 To maintain consistency with the field, we primarily used a binary cutoff to evaluate TMB-high vs TMB-low cohorts. This evidence concerns the gene NFE2L2 and neoplasm.